Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Debt / NOTE 2.250% 2/0
-
Market price (% of par)
-
63.92%
-
Total 13F principal
-
$515,601,127
-
Principal change
-
-$19,680,331
-
Total reported market value
-
$355,699,506
-
Number of holders
-
43
-
Value change
-
-$7,128,615,789
-
Number of buys
-
17
-
Number of sells
-
18
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q1 2023
As of 31 Mar 2023,
BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by
43 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$515,601,127
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, AMERIPRISE FINANCIAL INC, ARISTEIA CAPITAL LLC, Diameter Capital Partners LP, BRAIDWELL LP, DeepCurrents Investment Group LLC, INHERENT GROUP, LP, Aequim Alternative Investments LP, D. E. Shaw & Co., Inc., and ORBIMED ADVISORS LLC.
This page lists
44
institutional bondholders reporting positions
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.